{
    "root": "2f9c7d6f-7f0f-f9dd-e063-6294a90abf59",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Axumin",
    "value": "20250305",
    "ingredients": [
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "FLUCICLOVINE F-18",
            "code": "38R1Q0L1ZE"
        }
    ],
    "indications": "Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.",
    "contraindications": "Use appropriate radiation safety handling measures ( 2.1 ). Aseptically withdraw Axumin from its container and administer 370 MBq (10 mCi) as a bolus intravenous injection. ( 2.2 ). Initiate imaging 3 minutes to 5 minutes after administration. Scanning should start from mid-thigh and proceed to base of skull, with a total scan time of approximately 20 minutes to 30 minutes ( 2.4 ). The (radiation absorbed) effective dose associated with 370 MBq (10 mCi) of injected activity of Axumin is approximately 8Â mSv (0.8 rem) in an adult ( 2.6 ).",
    "warningsAndPrecautions": null,
    "adverseReactions": "None"
}